Sunitinib (Su) in Progressive Pancreatic Neuroendocrine Tumor (PNET) Administered in Different Treatment Lines Abstract #1871

Introduction: Su has shown PFS improvement in patients (pt) with PNET in phase III trial
Aim(s): We evaluate metastatic PNET treated with Su after failure of previous treatment (tr) including Everolimus (Ev), to assess efficacy and safety also in late lines of tr, and to evaluate the sequence Su after Ev
Materials and methods: From February 2011 to November 2016, 21 PNET pt with progressive disease were treated with Su 37,5 mg orally daily in 5 Italian centers. Grading was G1, G2 and unknown in 4,15 and 2 pt. Previous tr included SSA, Ev, chemotherapy, PRRT; 1 pt received Su in I line, 4 pt in II line, 6 pt in III line, 6 pt in IV line, 3 pt in V line, 1 pt in VI line. Ev was previously administered in 15 pt. Pt were followed for evidence of toxicity, response using RECIST criteria, and survival
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr. Riccardo Marconcini
Keywords: sunitinib

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2065 Sunitinib in Patients with Pre-Treated Pancreatic Neuroendocrine Tumors: A Real-World Study
Introduction: Besides data reported in a Phase-III trial, data on sunitinib in pancreatic Neuroendocrine Tumors (panNETs) are scanty.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment -Targeted therapies
Presenting Author: MD Maria Rinzivillo
#1729 Outstanding Response to Sunitinib in a Patient with Unresectable Retroperitoneal Paraganglioma
Introduction: Pheochromocitomas and Paragangliomas (PCs/PGLs) are rare neuroendocrine tumors arising from the adrenal medulla and extra-adrenal ganglia. Around 30-40% of these neoplasms are genetically determined. PCs/PGLs arising from the sympathetic chain can synthesize bioactive amines leading to typical syndromes, in contrast to parasympathetic PGLs that are mainly non-secretory.
Conference: 14th Annual ENETS conference (2017)
Category: Clinical cases/reports
Presenting Author: MD Sara Pusceddu
#892 Sunitinib in Gastroeneteropancreatic Neuroendocrine Tumor (GEP-NET) after Failure of Previous Treatments, Including Everolimus: A Series of Five Clinical Cases
Introduction: In a recent phase III study, Sunitinib has shown significant improvement of progression-free survival in patients with pancreatic NET.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr. Riccardo Marconcini
Keywords: sunitinib, everolimus
#1439 Sunitinib in the Treatment of Unresectable or Metastatic Gastroenteropancreatic Neuroendocrine Neoplasm: A Multicenter Retrospective Study in China
Introduction: Sunitinib has shown activity against pancreatic neuroendocrine tumors(NEN) in a global phase III clinical trial.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Chen Jie
#99 Gene mutations and Hypoxia Inducible Factor (HIF-1) expression as prognostic-predictive factors in pheochromocytomas/paragangliomas (P/P)
Introduction: P/P are rare tumors sporadically associated with familial disorders. In advanced/unresectable disease, no standard treatment has so far been well established. Recently a mutation of some genes (SDHB, SDHC, SDHD) involved in the pathogenesis of familial P/P was discovered. These mutations are often associated with an over-expression of HIF-1, which plays a central role in angiogenesis and cell proliferation. This pathway is known to be inhibited by some targeted therapies, such as sunitinib or sorafenib.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Emilio Bajetta